Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
European Journal of Cancer2022Vol. 175, pp. 204–213
Citations Over TimeTop 1% of 2022 papers
Claudia Angela Maria Fulgenzi, Jaekyung Cheon, Antonio D’Alessio, Naoshi Nishida, Celina Ang, Thomas U. Marron, Linda Y. Wu, Anwaar Saeed, Brooke Wietharn, Antonella Cammarota, Tiziana Pressiani, Nicola Personeni, Matthias Pinter, Bernhard Scheiner, Lorenz Balcar, Andrea Napolitano, Yi‐Hsiang Huang, Samuel Phen, Abdul Rafeh Naqash, Caterina Vivaldi, Francesca Salani, Gianluca Masi, Dominik Bettinger, Arndt Vogel, Martin Schönlein, Johann von Felden, Kornelius Schulze, Henning Wege, Peter R. Galle, Masatoshi Kudo, Lorenza Rimassa, Amit G. Singal, Rohini Sharma, Alessio Cortellini, Vincent E. Gaillard, Hong Jae Chon, David J. Pinato
Abstract
This global observational study confirms the reproducible safety and efficacy of atezolizumab plus bevacizumab in routine clinical practice. Within Child-Pugh-A criteria, the presence of PVTT and higher ALBI grade identify patients with poorer survival.
Related Papers
- → High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma(2020)21 cited
- → Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma(2011)5 cited
- → Significance of PIVKA-II in sorafenib therapy for advanced hepatocellular carcinoma(2010)1 cited
- [Advanced hepatocellular carcinoma: importance of clinical trials].(2015)
- → Heat Shock Protein 27 Expression Levels are associated with the Sensitivity of Hepatocellular Carcinoma Cells to Sorafenib(2022)